PB
The startup utilizes proprietary precision sequencing technology to identify molecular targets associated with diseases such as Alzheimer's, Parkinson's, advanced cancers, AIDS, Lyme, and COVID-19. This approach enables medical practitioners to develop targeted treatments based on specific disease mechanisms.
Updated 3 months ago
Funding
$1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup utilizes proprietary precision sequencing technology to identify molecular targets associated with diseases such as Alzheimer's, Parkinson's, advanced cancers, AIDS, Lyme, and COVID-19. This approach enables medical practitioners to develop targeted treatments based on specific disease mechanisms.